Department of Digestive Tract Diseases, Medical University of Lodz, Kopcinskiego 22, 90-153 Lodz, Poland.
Pancreatology. 2013 Jul-Aug;13(4):409-14. doi: 10.1016/j.pan.2013.04.198. Epub 2013 May 9.
Some authors suggest that adipocytokines contribute to the induction of pancreatic carcinogenesis as well as the development of endocrine insufficiency.
We evaluate the circulating concentrations of leptin, resistin and visfatin in patients with newly diagnosed pancreatic cancer (PC) and relationship between serum adipocytokines level and clinicopathological features of PC. Moreover the usefulness of those adipocytokines as possible biomarkers of endocrine pancreatic function in PC has been assessed.
The pilot study group consisted of 45 individuals (mean age 65.6 ± 11.5 years, BMI 21.8 ± 3.4 kg/m(2)) with newly diagnosed PC (within last 1-3 months) and 13 healthy individuals with age, gender and BMI matched to the study group. Among PC patients 18 (40%) had recently diagnosed diabetes. Fasting plasma leptin, resistin, visfatin concentrations were determined with ELISA (R&D Systems, Phoenix Pharmaceuticals) and insulin by RIA (DakoCytomation).
Patients with PC as compared to controls had significantly lower plasma leptin (40.6 ± 21.3 vs 63.2 ± 16.3 pg/mL; p < 0,0008). In contrast PC patients showed more than six fold higher level of resistin (126.2 ± 143.2 vs 18.9 ± 7.2 ng/mL; p < 0.009) than controls. The median plasma visfatin was 2.8 ± 1.8 ng/mL, which was not significantly different from the controls (3.8 ± 1.1 ng/mL). When PC patients with and without diabetes were considered separately, plasma leptin concentrations among nondiabetic patients were slightly, but not significantly higher (44.6 ± 21.0) as compared to diabetics (34.5 ± 20.7). Moreover there was no difference between visfatin and resistin level in PC, among patients with and without diabetes. No significant differences between serum level of leptin, visfatin and resistin and age, gender, BMI, smoking status, tumor localization, distant metastases and pain has been found.
The results of this study confirm previous findings that patients with newly diagnosed pancreatic cancer are characterized with lower level of leptin. This pilot study showed significantly higher resistin concentrations in patients with PC in comparison to healthy controls, which may be helpful in PC early diagnosis. Changes in leptin and resistin level in PC are not likely related to endocrine disorders.
一些作者认为脂肪细胞因子有助于诱导胰腺癌的发生以及内分泌功能不全的发展。
我们评估了新诊断的胰腺癌（PC）患者的循环瘦素、抵抗素和内脂素浓度，并研究了血清脂肪细胞因子水平与 PC 的临床病理特征之间的关系。此外，还评估了这些脂肪细胞因子作为 PC 内分泌胰腺功能的潜在生物标志物的有用性。
该初步研究组由 45 名个体（平均年龄 65.6 ± 11.5 岁，BMI 21.8 ± 3.4 kg/m²）组成，这些个体均为新诊断的 PC（在过去 1-3 个月内），另有 13 名年龄、性别和 BMI 与研究组相匹配的健康个体作为对照组。在 PC 患者中，18 名（40%）患者最近被诊断患有糖尿病。使用 ELISA（R&D Systems，Phoenix Pharmaceuticals）和 RIA（DakoCytomation）测定空腹血浆瘦素、抵抗素、内脂素浓度。
与对照组相比，PC 患者的血浆瘦素水平显著降低（40.6 ± 21.3 与 63.2 ± 16.3 pg/mL；p < 0.0008）。相反，PC 患者的抵抗素水平高出 6 倍以上（126.2 ± 143.2 与 18.9 ± 7.2 ng/mL；p < 0.009）。中位血浆内脂素为 2.8 ± 1.8 ng/mL，与对照组无显著差异（3.8 ± 1.1 ng/mL）。当单独考虑有和没有糖尿病的 PC 患者时，无糖尿病患者的血浆瘦素浓度略高（44.6 ± 21.0），但与糖尿病患者相比没有显著差异（34.5 ± 20.7）。此外，在有和没有糖尿病的 PC 患者中，瘦素、内脂素和抵抗素的水平之间没有差异。未发现血清瘦素、内脂素和抵抗素水平与年龄、性别、BMI、吸烟状况、肿瘤定位、远处转移和疼痛之间存在显著差异。
本研究结果证实了先前的发现，即新诊断的胰腺癌患者的瘦素水平较低。本初步研究显示，与健康对照组相比，PC 患者的抵抗素浓度显著升高，这可能有助于 PC 的早期诊断。PC 中瘦素和抵抗素水平的变化可能与内分泌紊乱无关。
